Immunomedics, Inc. (NASDAQ:IMMU) Director David M. Goldenberg sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, March 7th. The shares were sold at an average price of $17.50, for a total transaction of $350,000.00. Following the transaction, the director now owns 1,774,285 shares of the company’s stock, valued at approximately $31,049,987.50. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Immunomedics, Inc. (NASDAQ:IMMU) traded down $0.01 during trading hours on Monday, hitting $17.29. 1,775,357 shares of the stock traded hands, compared to its average volume of 2,020,000. Immunomedics, Inc. has a one year low of $5.00 and a one year high of $18.93. The company has a debt-to-equity ratio of 1.20, a quick ratio of 1.26 and a current ratio of 1.26. The company has a market cap of $2,630.00, a price-to-earnings ratio of -9.30 and a beta of 1.48.
Immunomedics (NASDAQ:IMMU) last posted its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.09). The firm had revenue of $0.60 million for the quarter, compared to the consensus estimate of $0.90 million. equities analysts forecast that Immunomedics, Inc. will post -0.96 earnings per share for the current year.
Several equities analysts have recently weighed in on the stock. ValuEngine lowered shares of Immunomedics from a “hold” rating to a “sell” rating in a research report on Monday, December 4th. BidaskClub upgraded shares of Immunomedics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 25th. TheStreet upgraded shares of Immunomedics from a “d” rating to a “c-” rating in a research report on Friday, February 9th. Zacks Investment Research lowered shares of Immunomedics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 15th. Finally, Jefferies Group raised their price objective on shares of Immunomedics from $22.00 to $27.00 and gave the company a “buy” rating in a research report on Wednesday, January 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. Immunomedics currently has a consensus rating of “Buy” and an average price target of $19.00.
COPYRIGHT VIOLATION NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2018/03/12/immunomedics-inc-immu-director-david-m-goldenberg-sells-20000-shares.html.
Immunomedics Company Profile
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.